The estimated Net Worth of Peter R Young is at least $883 Thousand dollars as of 28 June 2021. Peter Young owns over 3,000 units of Cel-Sci stock worth over $34,119 and over the last 21 years he sold CVM stock worth over $26,678. In addition, he makes $821,852 as Independent Director at Cel-Sci.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Sign up
Peter Young CVM stock SEC Form 4 insiders trading
Peter has made over 15 trades of the Cel-Sci stock since 2004, according to the Form 4 filled with the SEC. Most recently he bought 3,000 units of CVM stock worth $37,980 on 28 June 2021.
The largest trade he's ever made was buying 25,000 units of Cel-Sci stock on 19 June 2013 worth over $6,000. On average, Peter trades about 2,257 units every 140 days since 2003. As of 28 June 2021 he still owns at least 28,914 units of Cel-Sci stock.
You can see the complete history of Peter Young stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Peter Young biography
Dr. Peter R. Young Ph.D. serves as Independent Director of the Company. Dr. Young has been a senior executive within the pharmaceutical industry in the United States and Canada for most of his career, originally in organizations that are now part of Sanofi S.A. Over the last 20 years he has primarily held positions of Chief Executive Officer or Chief Financial Officer and has extensive experience with acquisitions and equity financing. Since November 2001, Dr. Young has been the President of Agnus Dei, LLC, which has acted as a partner in an organization managing immune system clinics which treats patients with diseases such as cancer, multiple sclerosis and hepatitis. Dr. Young was also the President and Chief Executive Officer of SRL Technology, Inc., a company involved in the development of pharmaceutical drug delivery systems. Between 1998 and 2001, Dr. Young was the Chief Financial Officer of Adams Laboratories, Inc., the developer of Mucinex®. Dr. Young received his Ph.D. in Organic Chemistry from the University of Bristol, England after obtaining his Bachelor's degree in Honors Chemistry, Mathematics and Economics. Subsequently, he qualified as a Fellow of the Chartered Institute of Management Accountants. CEL-SCI believes Dr. Young’s extensive knowledge of the life sciences industry, coupled with his business acumen and financial expertise, gives him the qualifications and skills to serve as a director, and the chair of CEL-SCI’s audit, nominating and compensation committees.
What is the salary of Peter Young?
As the Independent Director of Cel-Sci, the total compensation of Peter Young at Cel-Sci is $821,852. There are 5 executives at Cel-Sci getting paid more, with Geert Kersten having the highest compensation of $4,546,360.
How old is Peter Young?
Peter Young is 75, he's been the Independent Director of Cel-Sci since 2002. There are 4 older and 9 younger executives at Cel-Sci. The oldest executive at Cel-Sci Corp. is Dr. Daniel H. Zimmerman Ph.D., 80, who is the Sr. VP of Research & Cellular Immunology.
What's Peter Young's mailing address?
Peter's mailing address filed with the SEC is 8229 BOONE BLVD, STE 802, VIENNA, VA, 22182.
Insiders trading at Cel-Sci
Over the last 21 years, insiders at Cel-Sci have traded over $3,069,559 worth of Cel-Sci stock and bought 1,693,350 units worth $1,328,136 . The most active insiders traders include Clara Maximilian De, Geert R Kersten, and Eyal Talor. On average, Cel-Sci executives and independent directors trade stock every 50 days with the average trade being worth of $42,938. The most recent stock trade was executed by Robert Eugene Watson on 8 May 2024, trading 20,000 units of CVM stock currently worth $27,800.
What does Cel-Sci do?
cel-sci corporation engages in the research and development of immunotherapy for the treatment of cancer and infectious diseases. the company's lead investigational immunotherapy is multikine, which is under phase iii clinical trial for the treatment of head and neck cancer. its ligand epitope antigen presentation system (leaps), a pre-clinical patented t-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. the company also develops leaps-h1n1-dc; cel-2000 and cel-4000 are product candidates for the treatment of rheumatoid arthritis; and leaps cov-19, a product candidate to treat covid-19 coronavirus. cel-sci corporation has a collaboration agreement with the university of georgia's center for vaccines and immunology to develop leaps covid-19 immunotherapy. the company was founded in 1983 and is headquartered in vienna, virginia.
What does Cel-Sci's logo look like?
Complete history of Peter Young stock trades at Cel-Sci
Cel-Sci executives and stock owners
Cel-Sci executives and other stock owners filed with the SEC include:
-
Geert Kersten,
Chief Executive Officer, Treasurer, Director -
Patricia Prichep,
Senior Vice President - Operations, Corporate Secretary -
Eyal Talor,
Chief Scientific Officer -
Daniel Zimmerman,
Senior Vice President - Research, Cellular Immunology -
John Cipriano,
Senior Vice President - Regulatory Affairs -
Peter Young,
Independent Director -
Robert Watson,
Independent Director -
Bruno Baillavoine,
Independent Director -
Geert R. Kersten,
CEO, Principal Accounting & Financial Officer, Treasurer and Director -
Geert R. Kersten Esq.,
Chief Exec. & Financial Officer, Treasurer and Director -
Dr. Eyal Talor Ph.D.,
Chief Scientific Officer -
Patricia B. Prichep,
Sr. VP of Operations & Corp. Sec. -
Dr. Daniel H. Zimmerman Ph.D.,
Sr. VP of Research & Cellular Immunology -
John Cipriano,
Sr. VP of Regulatory Affairs -
Clara Maximilian De,
President -
Alexander G Esterhazy,
Director -
C Richard Kinsolving,
Director -
Gail K Naughton,
Director